Lindis Biotech
is a Germany-based biopharmaceutical company that develops and commercializes T cell-based immunotherapies for the treatment of cancer... Read moreLindis Biotech
is a Germany-based biopharmaceutical company that develops and commercializes T cell-based immunotherapies for the treatment of cancer... Read more
Est. Annual Revenue
<$1M
Est. Employees
<10
News
Feb 19, 2025
Manufacturing Chemist
Lindis Biotech: Celonic signs catumaxomab manufacturing agreement with Lindis Biotech
Feb 13, 2025
FinanzNachrichten
Lindis Biotech: Lindis Biotech GmbH: Lindis Biotech and Pharmanovia Announce European Marketing Authorization Approval for Catumaxomab, A First-In-Class Treatment for Malignant Ascites
Nov 21, 2024
Pharmabiz
Lindis Biotech: Pharmanovia partners with Lindis Biotech to commercialise catmaxomab to treat rare condition, malignant ascites
Nov 20, 2024
Pharamceutical Technology
Lindis Biotech: Pharmanovia signs license agreement for Lindis Biotech's catumaxomab
Nov 14, 2022
PharmaTimes
Lindis Biotech: Lindis biotech presents encouraging data from bladder cancer trial
Jun 01, 2022
FirstWord Pharma
Lindis Biotech: LINDIS Biotech Announces Online Publication of Abstract on Trifunctional Antibody CATUMAXOMAB for the Treatment of High-Risk Non-Muscle-Invasive Bladder Cancer at the ASCO 2022 Annual Meeting
Dec 21, 2021
centralcharts
Press Release: Lindis Biotech : DGAP-News: LINDIS Biotech Announces Formation of Advisory Board to Support Next Phase of Growth
Dec 21, 2021
MarketScreener
Lindis Biotech: LINDIS Biotech Announces Formation of Advisory Board to Support Next Phase of Growth
Jun 01, 2021
MarketScreener
Lindis Biotech: PRESS RELEASE : LINDIS Biotech Announces Publication of Patient Data Highlighting the Potential of Trifunctional Antibody CATUMAXOMAB for Treatment of Non-Muscle-Invasive Bladder Cancer in Peer-Reviewed Journal
Apr 13, 2021
MarketScreener
Lindis Biotech: Lindis Biotech GmbH : Reports Successful Initiation of Clinical Phase I Dose Escalation Study with the Trifunctional Antibody CATUMAXOMAB for Treatment of Non-Muscle-Invasive Bladder Cancer